Structural basis for subtype-specific inhibition of the P2X7 receptor

eLife

Volumn 5, Issue DECEMBER2016, 2016, Pages

  Karasawa, Akira ^a   Kawate, Toshimitsu ^a  

^a Department of Molecular Biology and Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; RECEPTOR SUBTYPE; PROTEIN BINDING;

ALLOSTERISM; ANIMAL CELL; ANISOTROPY; ARTICLE; BINDING SITE; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG BINDING; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; GENE; GENE CONSTRUCT; GENE SYNTHESIS; HUMAN; HUMAN CELL; IC50; LIGAND BINDING; NONHUMAN; P2X7 GENE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RECEPTOR BINDING ASSAY; RECEPTOR BLOCKING; SIZE EXCLUSION CHROMATOGRAPHY; STRUCTURE ANALYSIS; WHOLE CELL PATCH CLAMP; X RAY DIFFRACTION; ANIMAL; CHEMISTRY; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7;

EID: 85006870202     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.22153     Document Type: Article

References (47)

1. Acquas E, Wilson C, Fibiger HC. 1998. Pharmacology of sensory stimulation-evoked increases in frontal cortical acetylcholine release. Neuroscience 85:73-83. doi:10.1016/S0306-4522(97)00546-0,PMID:9607704
2. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica Section D Biological Crystallography 66:213-221. doi:10.1107/S0907444909052925,PMID:20124702
3. Bartlett R, Stokes L, Sluyter R. 2014. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacological Reviews 66:638-675. doi:10.1124/pr.113.008003,PMID:24928329
4. Bhattacharya A, Wang Q, Ao H, Shoblock JR, Lord B, Aluisio L, Fraser I, Nepomuceno D, Neff RA, Welty N, Lovenberg TW, Bonaventure P, Wickenden AD, Letavic MA. 2013. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. British Journal of Pharmacology 170:624-640. doi:10.1111/bph.12314,PMID:23889535
5. Bhattacharya A, Biber K. 2016. The microglial ATP-gated ion channel P2X7 as a CNS drug target. Glia 64:1772-1787. doi:10.1002/glia.23001,PMID:27219534
6. Burnstock G. 2013. Purinergic mechanisms and pain-an update. European Journal of Pharmacology 716:24-40. doi:10.1016/j.ejphar.2013.01.078,PMID:23524093
7. Burnstock G. 2014. Purinergic signalling: from discovery to current developments. Experimental Physiology 99: 16-34. doi:10.1113/expphysiol.2013.071951,PMID:24078669
8. Chen Y, Liu L. 2012. Modern methods for delivery of drugs across the blood-brain barrier. Advanced Drug Delivery Reviews 64:640-665. doi:10.1016/j.addr.2011.11.010,PMID:22154620
9. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN. 2005. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114:386-396. doi:10.1016/j.pain.2005.01.002,PMID:15777864
10. Di Virgilio F. 1995. The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunology Today 16:524-528. doi:10.1016/0167-5699(95)80045-X,PMID:7495489
11. Donnelly-Roberts DL, Namovic MT, Surber B, Vaidyanathan SX, Perez-Medrano A, Wang Y, Carroll WA, Jarvis MF. 2009. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology 56:223-229. doi:10.1016/j.neuropharm.2008.06.012,PMID:18602931
12. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS. 2007. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237-251. doi:10.1016/j.pain.2007.08.033,PMID:17920770
13. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallographica Section D Biological Crystallography 60:2126-2132. doi:10.1107/S0907444904019158,PMID:15572765
14. Evans PR, Murshudov GN. 2013. How good are my data and what is the resolution? Acta Crystallographica Section D Biological Crystallography 69:1204-1214. doi:10.1107/S0907444913000061,PMID:23793146
15. Finnerup NB, Sindrup SH, Jensen TS. 2010. The evidence for pharmacological treatment of neuropathic pain. Pain 150:573-581. doi:10.1016/j.pain.2010.06.019,PMID:20705215
16. Gold MS, Gebhart GF. 2010. Nociceptor sensitization in pain pathogenesis. Nature Medicine 16:1248-1257. doi:10.1038/nm.2235,PMID:20948530
17. Goldberg DS, McGee SJ. 2011. Pain as a global public health priority. BMC Public Health 11:770. doi:10.1186/1471-2458-11-770,PMID:21978149
18. Gum RJ, Wakefield B, Jarvis MF. 2012. P2X receptor antagonists for pain management: examination of binding and physicochemical properties. Purinergic Signalling 8:41-56. doi:10.1007/s11302-011-9272-5,PMID:22086553
19. Habermacher C, Dunning K, Chataigneau T, Grutter T. 2016. Molecular structure and function of P2X receptors. Neuropharmacology 104:18-30. doi:10.1016/j.neuropharm.2015.07.032,PMID:26231831
20. Hattori M, Gouaux E. 2012. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 485:207-212. doi:10.1038/nature11010,PMID:22535247
21. Ho BK, Gruswitz F. 2008. HOLLOW: Generating accurate representations of channel and interior surfaces in molecular structures. BMC Structural Biology 8:49. doi:10.1186/1472-6807-8-49,PMID:19014592
22. Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, Chandran P, Harris R, Medrano AP, Carroll W, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF. 2006a. A-740003 [N-(1-~[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. Journal of Pharmacology and Experimental Therapeutics 319:1376-1385. doi:10.1124/jpet.106.111559,PMID:16982702
23. Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, Chandran P, Harris R, Medrano AP, Carroll W, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF. 2006b. A-740003 [N-(1-~[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. Journal of Pharmacology and Experimental Therapeutics 319:1376-1385. doi:10.1124/jpet.106.111559,PMID:16982702
24. Kabsch W. 1976. A solution for the best rotation to relate two sets of vectors. Acta Crystallographica Section A 32:922-923. doi:10.1107/S0567739476001873
25. Kabsch W. 2010. XDS. Acta crystallographica. Section D, Biological crystallography 66:125-132. doi:10.1107/S0907444909047337,PMID:20124692
26. Kawate T, Gouaux E. 2006. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure 14:673-681. doi:10.1016/j.str.2006.01.013,PMID:16615909
27. Kawate T, Michel JC, Birdsong WT, Gouaux E. 2009. Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature 460:592-598. doi:10.1038/nature08198,PMID:19641588
28. Kenakin T. 2006. Data-driven analysis in drug discovery. Journal of Receptors and Signal Transduction 26:299-327. doi:10.1080/10799890600778300,PMID:16818378
29. Keystone EC, Wang MM, Layton M, Hollis S, McInnes IB, Team DCS, D1520C00001 Study Team. 2012. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Annals of the Rheumatic Diseases 71:1630-1635. doi:10.1136/annrheumdis-2011-143578,PMID:22966146
30. Mansoor SE, Lu W, Oosterheert W, Shekhar M, Tajkhorshid E, Gouaux E. 2016. X-ray structures define human P2X3 receptor gating cycle and antagonist action. Nature 538. doi:10.1038/nature19367,PMID:27626375
31. McGaraughty S, Chu KL, Namovic MT, Donnelly-Roberts DL, Harris RR, Zhang XF, Shieh CC, Wismer CT, Zhu CZ, Gauvin DM, Fabiyi AC, Honore P, Gregg RJ, Kort ME, Nelson DW, Carroll WA, Marsh K, Faltynek CR, Jarvis MF. 2007. P2X7-related modulation of pathological nociception in rats. Neuroscience 146:1817-1828. doi:10.1016/j.neuroscience.2007.03.035,PMID:17478048
32. Michel AD, Chambers LJ, Clay WC, Condreay JP, Walter DS, Chessell IP. 2007. Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. British Journal of Pharmacology 151:103-114. doi:10.1038/sj.bjp.0707196,PMID:17339830
33. Michel AD, Chambers LJ, Walter DS. 2008a. Negative and positive allosteric modulators of the P2X(7) receptor. British Journal of Pharmacology 153:737-750. doi:10.1038/sj.bjp.0707625,PMID:18071294
34. Michel AD, Clay WC, Ng SW, Roman S, Thompson K, Condreay JP, Hall M, Holbrook J, Livermore D, Senger S. 2008b. Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects. British Journal of Pharmacology 155:738-751. doi:10.1038/bjp.2008.306,PMID:18660826
35. North RA. 2002. Molecular physiology of P2X receptors. Physiological Reviews 82:1013-1067. doi:10.1152/physrev.00015.2002,PMID:12270951
36. North RA, Jarvis MF. 2013. P2X receptors as drug targets. Molecular Pharmacology 83:759-769. doi:10.1124/mol.112.083758,PMID:23253448
37. Nuttle LC, Dubyak GR. 1994. Differential activation of cation channels and non-selective pores by macrophage P2z purinergic receptors expressed in xenopus oocytes. The Journal of Biological Chemistry 269:13988-13996. PMID: 7514597
38. Schild HO. 1947. pA, a new scale for the measurement of drug antagonism. British Journal of Pharmacology and Chemotherapy 2:189-206. doi:10.1111/j.1476-5381.1947.tb00336.x,PMID:20258355
39. Smart OS, Neduvelil JG, Wang X, Wallace BA, Sansom MS. 1996. HOLE: a program for the analysis of the pore dimensions of ion channel structural models. Journal of Molecular Graphics 14:354-360. doi:10.1016/S0263-7855(97)00009-X,PMID:9195488
40. Sperlágh B, Illes P. 2014. P2X7 receptor: an emerging target in central nervous system diseases. Trends in Pharmacological Sciences 35:537-547. doi:10.1016/j.tips.2014.08.002,PMID:25223574
41. Steinberg TH, Newman AS, Swanson JA, Silverstein SC. 1987. ATP4-permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. The Journal of Biological Chemistry 262:8884-8888. PMID: 3597398
42. Stock TC, Bloom BJ, Wei N, Ishaq S, Park W, Wang X, Gupta P, Mebus CA. 2012. Efficacy and safety of CE-224, 535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. The Journal of Rheumatology 39:720-727. doi:10.3899/jrheum.110874,PMID:22382341
43. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. 1996. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272:735-738. doi:10.1126/science.272.5262.735,PMID:8614837
44. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 suite and current developments. Acta Crystallographica Section D Biological Crystallography 67:235-242. doi:10.1107/S0907444910045749,PMID:21460441
45. Wyllie DJ, Chen PE. 2007. Taking the time to study competitive antagonism. British Journal of Pharmacology 150:541-551. doi:10.1038/sj.bjp.0706997,PMID:17245371
46. Yan Z, Li S, Liang Z, Tomic´ M, Stojilkovic SS. 2008. The P2X7 receptor channel pore dilates under physiological ion conditions. The Journal of General Physiology 132:563-573. doi:10.1085/jgp.200810059,PMID:18852304
47. Yan Z, Khadra A, Li S, Tomic M, Sherman A, Stojilkovic SS. 2010. Experimental characterization and mathematical modeling of P2X7 receptor channel gating. Journal of Neuroscience 30:14213-14224. doi:10.1523/JNEUROSCI.2390-10.2010,PMID:20962242